Capricor Therapeutics (US.CAPR)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.CAPR · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 136.7% | ↑ |
| ROE | -12.2% | ↑ |
| Cash Conversion | - | → |
| D/E Ratio | 0.05 | ↓ |
| Gross Margin | - | → |
US.CAPR (Capricor Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 136.7% ↑ ROE -12.2% ↑ Cash Conversion - → D/E Ratio 0.05 ↓ Gross Margin - →
Key Metrics
US.CAPR (Capricor Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 136.7% ↑ROE -12.2% ↑Cash Conversion - →D/E Ratio 0.05 ↓Gross Margin - →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies